doxorubicin + cyclophosphamide + goserelin + paclitaxel

This is a four-drug combination regimen used primarily in the treatment of breast cancer. It consists of: - Doxorubicin, an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. - Cyclophosphamide, an alkylating agent that cross-links DNA strands and prevents cell division. - Paclitaxel, a taxane that stabilizes microtubules and inhibits their disassembly, blocking mitosis. - Goserelin, a gonadotropin-releasing hormone (GnRH) agonist that suppresses ovarian function by downregulating pituitary GnRH receptors after initial stimulation; this reduces estrogen production. The AC-T regimen (doxorubicin + cyclophosphamide followed by paclitaxel) is well-established for adjuvant or neoadjuvant therapy in early-stage or node-positive breast cancer[1][10]. The addition of goserelin is typically used for ovarian suppression in premenopausal women with hormone receptor-positive disease to enhance endocrine therapy efficacy. This multi-agent approach targets cancer cells through multiple mechanisms—DNA damage (doxorubicin/cyclophosphamide), mitotic arrest (paclitaxel), and hormonal suppression (goserelin)—to maximize antitumor activity.

Other names

AC-T with goserelindoxorubicin/cyclophosphamide/goserelin/paclitaxel combination